IP at risk in Europe, claims EFPIA
In its latest warning over the proposed Supplementary Protection Certification (SPC) manufacturing waiver, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has claimed that these proposals suggest that Europe is weakening its commitment to intellectual property (IP).
The EFPIA, which represents 40 of the biggest investors in life science research and development, is a long-term critic of changes to the SPC, a certificate that allows pharmaceutical manufacturers to extend the 20-year patent protection on their medicines by an additional five years.
Currently, European Union (EU)-based companies cannot produce generic or biosimilar versions of these medicines for sale in the EU during that time. Neither can they export them to countries where the SPC does not apply, or produce and stockpile medicines for the EU market in advance of the day of SPC expiry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze